AGN-193408 SR

· AbbVie

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AGN-193408 SR, covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension [Phase 1, Phase 2]